Cedric the Entertainer and Stand Up To Cancer Join Forces for a New PSA Campaign to Increase Awareness of Cancer Clinical Trials - Stand Up to Cancer

Press

Posted July 23, 2020

Cedric the Entertainer and Stand Up To Cancer Join Forces for a New PSA Campaign to Increase Awareness of Cancer Clinical Trials

LOS ANGELES – July 27, 2020 – Stand Up To Cancer® (SU2C) Ambassador and comedian Cedric the Entertainer has teamed up with SU2C for a new public service announcement (PSA) designed to educate and encourage cancer patients to explore treatment options available through clinical trials. The PSA is the third in a series of PSAs supporting Stand Up To Cancer’s Health Equity Initiative, which is aimed at increasing diversity in cancer clinical trials. The PSA launches in July and will run in print, digital and out-of-home outlets.

The new PSA follows campaigns by actors Sonequa Martin-Green and Jaime Camil, and features a personal call to action from Cedric the Entertainer to learn more about cancer clinical trials. Cedric the Entertainer, whose acting and producing credits include CBS’ The Neighborhood, Cedric the Entertainer Presents, and The Last O.G., has been supporting Stand Up To Cancer since 2018, and was inspired by his mother’s 2009 uterine cancer diagnosis to become an advocate for the cause.

“My mother’s cancer journey taught me about the value of advocating for yourself and knowing your options,” said Cedric the Entertainer. “Participation in cancer clinical trials is extremely low in the Black community, and I am proud to work with Stand Up To Cancer and take action to address this importance issue.”

“We’re honored Cedric the Entertainer has joined us to raise awareness about the importance and benefits of cancer clinical trials,” said Stand Up To Cancer CEO Sung Poblete, PhD, RN. “The incredible altruism of the entertainment community has helped us advance our goal of delivering more cutting-edge research and resources for cancer patients in diverse communities, who need our support now more than ever.”

SU2C’s Health Equity Initiative, announced in January 2020, aims to increase diversity in cancer clinical trials to ensure patients of all racial and ethnic backgrounds benefit equally from the potential of cancer treatments, and that research addresses differences in genetics, metabolism and physiology. Currently, data from the FDA shows only 4 percent of total cancer clinical trial participants are Black, and 5 percent are Hispanic, despite the fact that people of color have the highest mortality rates and shortest overall survival rates for most cancers.

SU2C has implemented new procurement requirements for all future research grant proposals to determine whether the research area of focus impacts a specific minority population. These procurement requirements will require that all proposals provide plans for patient recruitment and retention of historically underrepresented populations.

To learn more about cancer clinical trials, visit StandUpToCancer.org/ClinicalTrials. Cancer patients are particularly vulnerable to COVID-19, especially those contending with cancers of the lung or blood, and those whose treatment suppresses the immune system. For COVID-19 resources, visit StandUpToCancer.org/COVID19.

About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation, a 501(c)(3) charitable organization, was established in 2008 by media and entertainment leaders who utilize these communities’ resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of January 2020, more than 1,600 scientists representing more than 180 institutions are involved in SU2C-funded research projects.

Under the direction of our Scientific Advisory Committee, led by Nobel laureate Phillip A. Sharp, Ph.D., SU2C operates rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and ensure collaboration across research programs.

Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, Ph.D., R.N., serves as SU2C’s CEO.

For more information, visit StandUpToCancer.org.

# # #

Media Contacts:

Stand Up To Cancer
Kim Warden
Communications Manager
kwarden@su2c.org
424-283-3650

Meghan Gambichler
ID PR
su2c@id-pr.com
646-723-3800

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.